LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by DF Dent & Co. Inc.

DF Dent & Co. Inc. reduced its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 26.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 190,362 shares of the medical instruments supplier’s stock after selling 68,405 shares during the quarter. DF Dent & Co. Inc.’s holdings in LeMaitre Vascular were worth $17,540,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of LMAT. Copeland Capital Management LLC lifted its stake in shares of LeMaitre Vascular by 0.7% during the fourth quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier’s stock valued at $107,990,000 after buying an additional 8,623 shares during the period. State Street Corp lifted its stake in shares of LeMaitre Vascular by 3.6% during the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after purchasing an additional 28,525 shares during the period. Congress Asset Management Co. boosted its holdings in shares of LeMaitre Vascular by 1.8% during the fourth quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier’s stock worth $66,555,000 after purchasing an additional 13,009 shares during the last quarter. Geode Capital Management LLC grew its position in shares of LeMaitre Vascular by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier’s stock valued at $50,711,000 after purchasing an additional 7,737 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in LeMaitre Vascular by 2.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 195,752 shares of the medical instruments supplier’s stock valued at $18,037,000 after purchasing an additional 4,241 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on LMAT shares. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Lake Street Capital boosted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.25.

LeMaitre Vascular Stock Up 1.7 %

LeMaitre Vascular stock opened at $86.62 on Thursday. The firm has a fifty day moving average of $92.25 and a 200-day moving average of $94.31. LeMaitre Vascular, Inc. has a 52-week low of $62.39 and a 52-week high of $109.58. The firm has a market capitalization of $1.95 billion, a P/E ratio of 47.33, a PEG ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $55.81 million during the quarter, compared to analysts’ expectations of $55.99 million. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were paid a $0.20 dividend. The ex-dividend date of this dividend was Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.92%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company’s stock, valued at $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.